Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1/2 5Phase 1 5Phase 3 4Phase 2/3 3Phase NA 1Phase EARLY_PHASE1 1

Status

Withdrawn 1Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 3Dermatologic 1

Conditions

Glioblastoma 39Brain Neoplasms 17Astrocytoma 16Central Nervous System Neoplasms 9Oligodendroglioma 8Gliosarcoma 8Melanoma 7Glioma 7Neoplasms 5Recurrence 4Neoplasm Metastasis 3Neuroblastoma 2Ganglioneuroblastoma 2Diffuse Intrinsic Pontine Glioma 2Choroid Plexus Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Sarcoma, Ewing 1Sarcoma 1Rhabdoid Tumor 1Rare Diseases 1Optic Nerve Glioma 1Neurotoxicity Syndromes 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Neuroepithelial 1Neoplasms, Connective and Soft Tissue 1Neoplasms, Connective Tissue 1Neoplasms, Bone Tissue 1Neoplasms by Histologic Type 1Melanoma, Cutaneous Malignant 1

Interventions

Dexamethasone 28Rituximab 16pomalidomide 13Gemcitabine 12Lenalidomide 11Cisplatin 11Bortezomib 11Paclitaxel 10Cyclophosphamide 8Carboplatin 8carfilzomib 7selinexor 5daratumumab 5Drug Therapy 5Doxorubicin 5Cytarabine 5ibrutinib 4Vincristine 4Temozolomide 4Prednisone 4Docetaxel 4Calcium Dobesilate 4Bevacizumab 4Aspirin 4tisagenlecleucel 3Cetuximab 3Bendamustine Hydrochloride 3venetoclax 2ofatumumab 2galiximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Recurrence × Temozolomide × Clear all
NCT05718466 2023-07-17

Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy

Henry Ford Health System

Phase 3 Completed
35 enrolled 13 charts
CNS

Glioblastoma, Recurrence

NCT02761070 2023-03-08

RE-GEND

Kyorin University

Phase 3 Unknown
146 enrolled
CNS

Glioblastoma, Recurrence, Disease Progression

NCT02288897 2022-01-19

PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Provectus Pharmaceuticals

Phase 3 Terminated
20 enrolled 13 charts
Dermatologic

Melanoma, Recurrence

NCT01260103 2017-07-26

Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma

Burzynski Research Institute

Phase 3 Withdrawn
CNS

Recurrence, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡